FDA/CDRH Scientific Technical Capacity for Regulatory Review

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

FDA OFFICE OF ACQ GRANT SVCS

Contract Value

Not provided

Codes & Classification
Solicitation Number

75F40127Q00006

NAICS

541611 - Administrative Management and General Management Consulting Services

Classification Code

R499

Additional Details
Set Aside

NONE

Place of Performance

Silver Spring, Maryland, UNITED STATES

SourceSAM
Documents2
The U.S. Food and Drug Administration (FDA), through its Office of Acquisition and Grant Services, has issued a Sources Sought Notice (SSN) for the project titled "FDA/CDRH Scientific Technical Capacity for Regulatory Review." This notice, identified by procurement number 75F40127Q00006, is intended solely for market research and planning purposes and does not constitute a solicitation or a request for quotation. The FDA is seeking to identify potential qualified vendors, including both large and small businesses, capable of providing advanced scientific and technical consulting services to support the Center for Devices and Radiological Health (CDRH) in its regulatory review activities. Purpose and Scope: The primary aim of this procurement activity is to enhance the scientific and technical capacity of the CDRH by engaging expert consultants across a broad spectrum of disciplines. These consultants will assist CDRH Offices in regulatory review processes throughout the total product lifecycle of medical devices. The scope encompasses support for scientific, engineering, clinical, and regulatory activities, including but not limited to research, cybersecurity and digital health consultations, regulatory consultations and auditing, and engagement with industry and patient stakeholders. Key Requirements and Objectives: The FDA requires consultants with demonstrated expertise in a wide array of science, engineering, and clinical specialties. Areas of interest include Anesthesiology, Biology, Biomedical Engineering, Chemistry, Clinical Laboratory Testing, Computer Science and Engineering, Consumer Safety, Cybersecurity, Data Science, Dentistry, Digital Health, Epidemiology, Gastroenterology, General Engineering, Health Science, Infectious Diseases, Interdisciplinary Engineering/Science, Molecular Testing, Neurology, Optics, Patient Engagement, Physics, Psychiatry, Public Health, Pulmonology, Medical Device Reprocessing, Social Science, Software Engineering, Statistics and Biostatistics, Sterilization, Toxicology, Urology, Veterinary Medicine, and Virology. The objective is to secure critical scientific expertise and capacity to support the evaluation of performance, safety, and effectiveness of medical devices that are approved, cleared, licensed, or authorized by the FDA for the treatment, prevention, or diagnosis of medical conditions. Expected Deliverables: While this notice is not a solicitation, it anticipates the need for professional consulting services that will provide regulatory review support and scientific input across the aforementioned specialties. The anticipated period of performance includes one base year and four option years, indicating a long-term engagement for selected vendors. Contracting Entity and Location: The contracting entity is the FDA Office of Acquisition and Grant Services, a federal office under the Department of Health and Human Services. The place of performance is Silver Spring, Maryland, USA. Classification Codes and Procurement Type: The relevant NAICS code is 541611 (Administrative Management and General Management Consulting Services), with the 2022 version year. The Product Service Code is R499. There are no set-aside requirements specified for this procurement, meaning it is open to all business sizes and classifications. Special Considerations: This SSN is not a solicitation and does not obligate the government to award a contract. Responses are for informational purposes only and will be used to inform future acquisition strategies. Vendors are encouraged to provide feedback on the draft Statement of Work (Attachment A) and complete the Vendor Feedback Form (Attachment B). Responses should include company information, business size classification, and answers to specific questions regarding small business status, disadvantaged business status, HUBZone certification, woman-owned status, and veteran-owned status. Submission Instructions and Contact Information: Interested parties should submit their responses via email to Melinda Kim, Contract Specialist ([email protected]), with a copy to Nicholas Bisher, Contracting Officer ([email protected]), by 2:00 PM Eastern Standard Time on November 17, 2026. The subject line should reference "Vendor Response to SSN 75F40127Q00006." The maximum page limit for responses is 15 pages (Times New Roman, font size 11 or larger), excluding the Vendor Feedback Form. Attachments: - Attachment A: Draft Statement of Work - Attachment B: Vendor Feedback Form Additional Information: This notice remains active and can be accessed via SAM.gov at https://sam.gov/opp/d56982b0e91741e280535997bfdfdc96/view. Contractors should note that participation in this SSN does not preclude involvement in any future solicitation, should one be issued. Summary for Contractors: This opportunity is ideal for firms with deep expertise in scientific, engineering, and clinical consulting, particularly those with experience in medical device regulatory review and related scientific activities. The FDA is seeking to build a robust pool of consultants to support its mission-critical regulatory functions. Contractors should carefully review the draft Statement of Work and provide comprehensive feedback to help shape the final requirements. The absence of set-aside restrictions makes this an inclusive opportunity for all qualified vendors. Firms interested in supporting the FDA’s regulatory review capacity are encouraged to respond and demonstrate their capabilities.